PCM
VERA icon

Prelude Capital Management’s Vera Therapeutics VERA Stock Holding History

Prelude Capital Management’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.2M Sell
29,926
-145
-0.5% -$6.25K 0.09% 261
2025
Q4 		$1.52M Sell
30,071
-16,480
-35% -$585K 0.11% 197
2025
Q3 		$1.35M Buy
46,551
+20,951
+82% +$485K 0.11% 241
2025
Q2 		$603K Buy
+25,600
New +$576K 0.06% 386

Other funds holding VERA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prelude Capital Management's VERA Position: Q1 2026 in Review

Prelude Capital Management reduced its Vera Therapeutics (VERA) stake by 0.48% in Q1 2026, selling an estimated $6.25K and leaving 29,926 shares worth $1.2M. The position accounts for 0.09% of the portfolio, ranked #261.

Prelude Capital Management first reported a position in VERA in Q2 2025 and has held it in 4 quarters since. The position peaked at $1.52M in Q4 2025. 229 funds tracked by Wall St. Rank hold VERA as of Q1 2026.

  • Prelude Capital Management held 29,926 shares of Vera Therapeutics worth $1.2M as of Q1 2026.
  • Prelude Capital Management sold 145 Vera Therapeutics shares in Q1 2026, an estimated $6.25K.
  • Vera Therapeutics made up 0.09% of Prelude Capital Management's portfolio in Q1 2026, its #261 holding.
  • Prelude Capital Management first reported a position in Vera Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Prelude Capital Management's Vera Therapeutics position peaked at $1.52M in Q4 2025.
  • 229 funds tracked by Wall St. Rank held Vera Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.